BACKGROUND: Survival in frontotemporal dementia (FTD) is not well understood. We conducted a mixed effects meta-analysis of survival in FTD to examine phenotype differences and contributory factors. METHODS: The PubMed, Medline, EMBASE, CINAHL, PsycINFO and Cochrane databases were searched for studies describing survival or natural history of behavioral variant FTD (bvFTD), progressive non-fluent aphasia (PNFA), semantic dementia (SD), FTD with amyotrophic lateral sclerosis (FTD-ALS), progressive supranuclear palsy and corticobasal degeneration. There were no language restrictions. RESULTS: We included 27 studies (2,462 subjects). Aggregate mean and median survival were derived for each phenotype and, for comparison, Alzheimer's disease (AD) (using data from the selected studies). Survival was shortest in FTD-ALS (2.5 years). Mean survival was longest in bvFTD and PNFA (8 years) and median survival in SD (12 years). AD was comparable in survival to all except FTD-ALS. Age and sex did not affect survival; the education effect was equivocal. Heterogeneity in FTD survival was largely, but not wholly, explained by phenotypes. CONCLUSIONS: Survival differs for FTD phenotypes but, except for FTD-ALS, compares well to AD survival. Elucidating the potential causes of within-phenotype heterogeneity in survival (such as complicating features and comorbidities) may open up opportunities for tailored interventions.
BACKGROUND: Survival in frontotemporal dementia (FTD) is not well understood. We conducted a mixed effects meta-analysis of survival in FTD to examine phenotype differences and contributory factors. METHODS: The PubMed, Medline, EMBASE, CINAHL, PsycINFO and Cochrane databases were searched for studies describing survival or natural history of behavioral variant FTD (bvFTD), progressive non-fluent aphasia (PNFA), semantic dementia (SD), FTD with amyotrophic lateral sclerosis (FTD-ALS), progressive supranuclear palsy and corticobasal degeneration. There were no language restrictions. RESULTS: We included 27 studies (2,462 subjects). Aggregate mean and median survival were derived for each phenotype and, for comparison, Alzheimer's disease (AD) (using data from the selected studies). Survival was shortest in FTD-ALS (2.5 years). Mean survival was longest in bvFTD and PNFA (8 years) and median survival in SD (12 years). AD was comparable in survival to all except FTD-ALS. Age and sex did not affect survival; the education effect was equivocal. Heterogeneity in FTD survival was largely, but not wholly, explained by phenotypes. CONCLUSIONS: Survival differs for FTD phenotypes but, except for FTD-ALS, compares well to AD survival. Elucidating the potential causes of within-phenotype heterogeneity in survival (such as complicating features and comorbidities) may open up opportunities for tailored interventions.
Authors: Christopher B Morrow; Jeannie-Marie Sheppard Leoutsakos; Chiadi U Onyike Journal: Am J Geriatr Psychiatry Date: 2021-07-28 Impact factor: 7.996
Authors: Adam L Boxer; Michael Gold; Howard Feldman; Bradley F Boeve; Susan L-J Dickinson; Howard Fillit; Carole Ho; Robert Paul; Rodney Pearlman; Margaret Sutherland; Ajay Verma; Stephen P Arneric; Brian M Alexander; Bradford C Dickerson; Earl Ray Dorsey; Murray Grossman; Edward D Huey; Michael C Irizarry; William J Marks; Mario Masellis; Frances McFarland; Debra Niehoff; Chiadi U Onyike; Sabrina Paganoni; Michael A Panzara; Kenneth Rockwood; Jonathan D Rohrer; Howard Rosen; Robert N Schuck; Holly D Soares; Nadine Tatton Journal: Alzheimers Dement Date: 2020-01-06 Impact factor: 21.566
Authors: Carrie Caswell; Corey T McMillan; Sharon X Xie; Vivianna M Van Deerlin; EunRan Suh; Edward B Lee; John Q Trojanowski; Virginia M-Y Lee; David J Irwin; Murray Grossman; Lauren M Massimo Journal: Neurology Date: 2019-09-19 Impact factor: 9.910
Authors: Gesine Respondek; Carolin Kurz; Thomas Arzberger; Yaroslau Compta; Elisabet Englund; Leslie W Ferguson; Ellen Gelpi; Armin Giese; David J Irwin; Wassilios G Meissner; Christer Nilsson; Alexander Pantelyat; Alex Rajput; John C van Swieten; Claire Troakes; Keith A Josephs; Anthony E Lang; Brit Mollenhauer; Ulrich Müller; Jennifer L Whitwell; Angelo Antonini; Kailash P Bhatia; Yvette Bordelon; Jean-Christophe Corvol; Carlo Colosimo; Richard Dodel; Murray Grossman; Jan Kassubek; Florian Krismer; Johannes Levin; Stefan Lorenzl; Huw Morris; Peter Nestor; Wolfgang H Oertel; Gil D Rabinovici; James B Rowe; Thilo van Eimeren; Gregor K Wenning; Adam Boxer; Lawrence I Golbe; Irene Litvan; Maria Stamelou; Günter U Höglinger Journal: Mov Disord Date: 2017-05-13 Impact factor: 10.338
Authors: Alexander G Murley; Matthew A Rouse; Ian T S Coyle-Gilchrist; P Simon Jones; Win Li; Julie Wiggins; Claire Lansdall; Patricia Vázquez Rodríguez; Alicia Wilcox; Karalyn Patterson; James B Rowe Journal: J Neurol Neurosurg Psychiatry Date: 2021-02-09 Impact factor: 13.654